July 12th 2023
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
July 5th 2023
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
June 28th 2023
Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
June 21st 2023
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
May 5th 2023
Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
April 28th 2023
Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
April 21st 2023
A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.
Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.
April 14th 2023
In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.
A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.
April 7th 2023
Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.
Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.
July 12th 2017
Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses the applicability of liquid biopsies in gastrointestinal cancers.
June 30th 2017
Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.